
Conference Coverage
about 1 month ago
AAO 2026: Rethinking dry eye as a spectrum of ocular painabout 1 month ago
AAO 2026: Preventing complications in uveitic cataract surgeryabout 1 month ago
AAO 2026: Setting realistic expectations with refractive IOLsabout 1 month ago
AAO 2026: Comprehensive ophthalmologists are the uveitis front lineabout 1 month ago
AAO 2026: The optic nerve is the barrier to sight in eye transplantTrending on the Eye Care Network
Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3 billion
Dazodalibep data put Sjögren screening in focus for ophthalmologists
MacuMira receives CE Mark for microcurrent treatment of dry AMD
Q&A: What the FDA’s class-wide NAION warning on GLP-1s means for eye care
Genetic risk score forecasts glaucoma severity decades out
Latest News

MacuMira receives CE Mark for microcurrent treatment of dry AMD

Genetic risk score forecasts glaucoma severity decades out

The important role of midface support in undereye rejuvenation

Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3 billion

Q&A: Caroline R. Baumal, MD, from academic retina to the C-suite and back | Eichenbaum Acorns

Shorts










Digital Edition



Podcasts
Continuing Medical Education
All News

A systemic Sjögren therapy would make earlier identification more actionable for ophthalmologists, Esen K. Akpek, MD, said.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Retinal thickness fell by more than 100 µm within 8 weeks in each case

Two cases highlight when to start therapy in extensive and early atrophy

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

Fluid decreased in vein occlusion, AMD, and DME on aflibercept 8 mg or faricimab.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.

Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.

The once-daily combination drop is approved by the FDA to treat presbyopia.

Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME.

The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.

The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.

VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.

From the first BLA acceptance for a gene-agnostic optogenetic therapy to the first pivotal gene therapy trial in geographic atrophy, these are the retinal gene therapy milestones of 2026.

Kiril Kiprovski, MD, of NYU Langone shares clinical clues and bedside tests for spotting Lambert-Eaton myasthenic syndrome.





























